CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS

Patent №

US 7,892,829

Granted

2011-02-22

Filed 2009

Owner

OSIRIS THERAPEUTICS, INC.

+1 more

Lab

AI components

1

planning

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

12395949

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

PlanningA61K 35/28A61P 9/00A61P 9/04A61P 9/10A61P 21/00C12N 5/0657C12N 5/0663A61K 35/12+6 more

AI classification

Planning0.97
Knowledge representation0.03
Natural language0.00
Evolutionary computation0.00
Speech0.00
Machine learning0.00
AI hardware0.00
Vision0.00

Ownership

OSIRIS THERAPEUTICS, INC.

assignment · 241650865

MESOBLAST INTERNATIONAL SÀRL

assignment · 315330828

Assignors

PITTENGER, MARK F., GORDON, STEPHEN L., MACKAY, ALASTAIR MORGAN, MARTIN, BRADLEY J.

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC